Citadel Advisors’s Allarity Therapeutics ALLR Stock Holding History
Bought
Maintained
Sold
Other funds holding ALLR
MCM
HF
Citadel Advisors's ALLR Position: Q2 2026 in Review
Citadel Advisors opened a new position in Allarity Therapeutics (ALLR) in Q2 2026: 91,748 shares worth $118K. The stake represents ﹤0.01% of the portfolio and ranks #12551 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ALLR as recently as Q4 2025.
Citadel Advisors first reported a position in ALLR in Q3 2023 and has held it in 4 quarters since. The position peaked at $149K in Q3 2025. 20 funds tracked by Wall St. Rank hold ALLR as of Q2 2026.
- Citadel Advisors held 91,748 shares of Allarity Therapeutics worth $118K as of Q2 2026.
- Allarity Therapeutics was a new Citadel Advisors position in Q2 2026.
- Allarity Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12551 holding.
- Citadel Advisors first reported a position in Allarity Therapeutics in Q3 2023 and has held it in 4 quarters since.
- Citadel Advisors's Allarity Therapeutics position peaked at $149K in Q3 2025.
- 20 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.